Olvidé mi contraseña
Asóciese a SIIC en Internet para utilizar sin límites tanto siicsalud como la totalidad de los servicios bibliográficos de la institución.
Lectura recomendada:
Bisphosphonates and RANK Ligand Inhibitors for the Treatment and PRevention of Metastatic Bone Disease
European Journal of Cancer, 46(7):1211-1222
Lectura recomendada:
Cutaneous Squamous Cell Carcinoma (SCC) of the Head and Neck: Risk Factors of Overall and Recurrence-Free Survival
European Journal of Cancer, 46(9):1563-1572
Lectura recomendada:
Outcomes and Tolerability of Chemoradiation Therapy for Pancreatic Cancer Patients Aged 75 Years or Older
International Journal of Radiation Oncology Biology Physics, 77(4):1171-1177
Lectura recomendada:
Chemoradiotherapy with or without AE-941 in Stage III Non-Small Cell Lung Cancer: A Randomized Phase III Trial
Journal of the National Cancer Institute, 102(12):859-865
Lectura recomendada:
Adjuvant Pancreatic Cancer Therapy: No One Should Go It Alone or Be Left Behind
International Journal of Radiation Oncology Biology Physics, 77(3):645-647
Lectura recomendada:
Cyclooxygenase-2 Inhibitor NS398 Enhances Radiosensitivity of Radioresistant Esophageal Cancer Cells by Inhibiting AKT Activation and Inducing Apoptosis
Cancer Investigation, 28(7):679-688
¿Para qué uso fue aprobada la ixabepilona en los EE.UU.?
Introducción:
La ixabepilona es un análogo semisintético de la epotilona B, que demostró alta actividad antimicrotubular y baja susceptibilidad a los mecanismos de resistencia.
Lectura recomendada:
Analysis of Overall Survival from a Phase III Study of Ixabepilone Plus Capecitabine versus Capecitabine in Patients with MBC Resistant to Anthracyclines and Taxanes
Breast Cancer Research and Treatment, 122(2):409-418
Lectura recomendada:
Evidence-Based Treatment for Advanced Germ Cell Tumor of the Testis With a Case Illustration
Journal of the Chinese Medical Association, 73(7):343-352
Lectura recomendada:
Effect of Patient Age on Management Decisions in Breast Cancer: Consensus from a National Consultation
Oncologist, 15(7):657-664
Señale la opción correcta con respecto al trastuzumab.
Introducción:
La droga de primera línea para el tratamiento del cáncer mamario avanzado es el trastuzumab, un antagonista del receptor para el factor de crecimiento epidérmico.
Lectura recomendada:
Underuse of Anthracyclines in Women with HER-2+ Advanced Breast Cancer
Oncologist, 15(7):665-672
Lectura recomendada:
Vaccination Against Human Papilloma Virus (HPV): Epidemiological Evidence of HPV in Non-Genital Cancers
Pathology Oncology Research : POR,
Lectura recomendada:
Role of Tumor Supressor and Angiogenesis Markers in Prediction of Recurrence of Non Muscle Invasive Bladder Cancer
Pathology Oncology Research : POR,